IP Library Granted Patent US 12661373
Granted Patent B2
US 12661373 · App. 17/259,458 · Granted Jun 23, 2026

Electrochemically activated salt solution

Inventors: Mihran Baronian (Toffen, CH); Fabio Carli (Trieste, IT); Elisabetta Chiellini (Trieste, IT); Ernest Baehler (Egg, CH)
Assignee: AZAD PHARMA AG
A61K33/22A61K9/0048A61K9/08A61K33/20A61K33/42A61P27/02A61P31/04A61P31/12C25B1/26C25B11/02
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12661373
App. No.
17/259,458
Granted
Jun 23, 2026
Kind
B2
Abstract

The present application refers to an electrochemically activated salt solution (ECAS), its production, and its use for treating infections.

Claims (26)

1 . A closed high-density polyethylene (HDPE) container comprising:

an electrochemically activated salt solution (ECAS) stored in the closed HDPE container, wherein the ECAS comprises:

a content of total chlorine of between 100 and 450 mg/l,

a content of chloride of between 3 and 7 g/l,

a redox potential of +700 to +1,050 mV,

an osmolality of 250-350 mOsm/kg,

a pH value of 7.1-7.8, and

at least one of boric acid, a salt of boric acid, phosphoric acid, and a salt of phosphoric acid,

wherein, if present, the boric acid or the salt of boric acid is in an amount of 0.1-500 g/l,

wherein, if present, the phosphoric acid or the salt of phosphoric acid is in an amount of 0.1-100 g/l, and

wherein the redox potential of the ECAS stored in the closed HDPE container is reduced by 10% or less after storage for one year at 20° C.

2 . The HDPE container of claim 1 , wherein the ECAS comprises the phosphoric acid or the salt thereof.

3 . The HDPE container of claim 1 , wherein the ECAS comprises the boric acid or the salt thereof.

4 . The HDPE container of claim 1 , wherein the ECAS further comprises hypochlorite ions and/or hypochlorous acid.

5 . The HDPE container of claim 1 , wherein the ECAS further comprises at least one viscosity-increasing agent.

6 . The HDPE container of claim 1 , wherein the ECAS does not comprise an additional therapeutically active agent.

7 . The HDPE container of claim 1 , wherein the ECAS does not comprise an additional preservative.

8 . A process for producing the ECAS stored in the HDPE container of claim 1 , the process comprising:

(i) electrolyzing an aqueous chloride solution in an electrolysis reactor,

(ii) optionally adding the at least one of boric acid, the salt of boric, phosphoric acid, and the salt of phosphoric acid,

(iii) optionally diluting the ECAS by adding water for injection, and

(iv) storing the ECAS in the HDPE container.

9 . The process of claim 8 , wherein the electrolysis is conducted at a current of 10.0-30.0 A.

10 . The HDPE container of claim 1 , wherein said redox potential of the ECAS is +700 to +1,000 mV.

11 . The HDPE container of claim 4 , wherein said hypochlorite ions and/or hypochlorous acid of the ECAS are in a total concentration of 10 to 1000 mg/l.

12 . The HDPE container of claim 1 , wherein the redox potential of said ECAS is reduced by 30% or less after 24 months of storage.